Reducing Vaccine Preventable Diseases In Children: Using National Active Hospital-based Surveillance To Evaluate And Improve Immunisation Program Performance
Funder
National Health and Medical Research Council
Funding Amount
$1,049,916.00
Summary
This proposal aims to evaluate and improve upon immunisation policy and programs for the prevention of severe childhood influenza and pertussis. Using our successful Paediatric Active Enhanced Disease Surveillance (PAEDS) network in 6 major children's hospitals across Australia, we will identify gaps in the evidence base needed to better control influenza and pertussis and in particular to ensure programs are delivered in such a way so as to address health inequalities.
EFFECTIVENESS OF INFLUENZA AND PNEUMOCOCCAL VACCINATION IN PREVENTING HOSPITALISATION DUE TO PNEUMONIA IN OLDER PERSONS
Funder
National Health and Medical Research Council
Funding Amount
$258,475.00
Summary
Flu and pneumococcus remain important causes of illness and death in Australia. They can cause pneumonia and severe respiratory illness, including death, especially in older people. This is because natural immunity against infections tends to decrease with age. Vaccination against flu and pneumococcus is therefore recommended for all persons aged 65 years or older, but only in Victoria are both vaccines publicly funded. The Victorian initiative appears to have had a marked impact on improving va ....Flu and pneumococcus remain important causes of illness and death in Australia. They can cause pneumonia and severe respiratory illness, including death, especially in older people. This is because natural immunity against infections tends to decrease with age. Vaccination against flu and pneumococcus is therefore recommended for all persons aged 65 years or older, but only in Victoria are both vaccines publicly funded. The Victorian initiative appears to have had a marked impact on improving vaccination coverage, but its impact on disease has never been assessed. This study will estimate vaccination coverage, missed vaccination opportunities, effectiveness of flu and pneumococcal vaccines in preventing hospitalisation for pneumonia, and cost-effectiveness of the currently funded vaccination program in this age group. This is considered a priority because of the serious but preventable nature of the diseases caused by these infections. This study will improve awareness of the importance of vaccination among individuals, and given the high estimated vaccine coverage in older Victorians, is well placed to provide the first available evidence for or against effectiveness and cost-effectiveness of flu and pneumococcal vaccination in older Australians. The results may have major implications for public health policy in Victoria and elsewhere in Australia.Read moreRead less
Economic Evaluation Of Alternative Pneumococcal Vaccination Strategies
Funder
National Health and Medical Research Council
Funding Amount
$242,894.00
Summary
Pneumococcal vaccination is a readily available preventive strategy that can offer substantial protection to the elderly but it is important that we carefully evaluate the different potential strategies to ensure the most (cost-) effective approach to prevention is identified. This grant will explore alternative strategies to control pneumococcal-related disease in elderly Australians using the available vaccines.
First Line Treatments For Common Musculoskeletal Conditions: Establishing Effectiveness And Cost-effectiveness
Funder
National Health and Medical Research Council
Funding Amount
$452,583.00
Summary
Dr Christine Lin is an outstanding young researcher whose research focuses on investigating the effectiveness and cost-effectiveness (value-for-money) of treatments for common musculoskeletal conditions. These conditions, such as back pain and fracture, are a major cause of disability in Australia and abroad. Dr Lin will lead a series of large clinical studies with an aim to improve patient outcomes while minimising the economic burden on the individual, health system and society.
Advanced Population-based Methods To Evaluate And Inform Immunisation Policy And Practice
Funder
National Health and Medical Research Council
Funding Amount
$425,048.00
Summary
Despite the overall success of immunisation programs, preventable infections continue to occur, with Aboriginal children suffering the most. I will study the health and vaccination records for 1.95 million children (98,000 Aboriginal) in New South Wales and Western Australia to see who is most at risk of vaccine preventable infections and why. The findings will aid development of strategies to target high-risk children and to optimise the benefits obtained from Australia’s immunisation program.
Enabling Technologies For Design And Delivery Of Novel Vaccines Against Infectious Diseases And Cancer.
Funder
National Health and Medical Research Council
Funding Amount
$925,346.00
Summary
This grant will support research necessary to develop the next generation of vaccines. These will combat diseases caused by bacteria and viruses and can also be used to fight cancer. The broad range of application is made possible through the incorporation of simple molecular features that activate the immune system. The intellectual property that has been developed is protected by a patent portfolio some patents of which are already licenced to the pharmaceutical industry.
Enhancing Australia's Pandemic Influenza Vaccine Output By Increasing The Yeild Of Vaccine From Eggs
Funder
National Health and Medical Research Council
Funding Amount
$251,517.00
Summary
Influenza epidemics cause significant morbidity and mortality, particularly amongst the young and elderly. Unlike other vaccines, a new flu vaccine formulation needs to be prepared each year from the currently circulating strain. This involves a long process of preparing new seed vaccine stock, which is then tested, manufactured and distributed. The situation is even more complicated by the ability of different influenza strains to reassort with others. An example of current major concern is the ....Influenza epidemics cause significant morbidity and mortality, particularly amongst the young and elderly. Unlike other vaccines, a new flu vaccine formulation needs to be prepared each year from the currently circulating strain. This involves a long process of preparing new seed vaccine stock, which is then tested, manufactured and distributed. The situation is even more complicated by the ability of different influenza strains to reassort with others. An example of current major concern is the possibility of deadly avian flu viruses, such as H5N1, to gain the capacity to directly infect humans by recombining with a human strain and thereby starting a new global pandemic. When the next influenza pandemic occurs, the availability of a vaccine will be of the highest priority and early supply of vaccines will save millions of lives. Since vaccination is the only sustainable defense, we face an urgent need to have the capacity to supply large numbers of vaccine doses of influenza vaccines within a short period of time. Currently, the only way of producing flu vaccines is in eggs. The speed of vaccine supply is totally dependant on the yield of vaccine from eggs and the number of eggs that can be processed at any one time. Since there are severe constraints on the number of eggs that can be simultaneously processed, the limiting factor that can be addressed is the actual yield of vaccine per egg. The aim of this project is the develop methods that allow higher levels of vaccine virus to grow in eggs. We will take a multi-pronged approach to enhancing influenza vaccine production that are directed toward increasing the capacity of eggs to promote virus replication, as well as towards the vaccine strain to boost its ability to replicate in the egg. The outcome will be an enhanced capacity for vaccine manufacturers to quickly and effectively expand vaccine supplies which will directly impact on global morbidity and mortality during a flu pandemic.Read moreRead less
The Effectiveness Of Rehabilitation And The Efficiency Of Health Service Delivery In Musculoskeletal Conditions
Funder
National Health and Medical Research Council
Funding Amount
$292,639.00
Summary
Musculoskeletal conditions, such as arthritis and back pain, present a huge burden to the Australian society. The purpose of this research is to establish rehabilitation programs that are effective in reducing disability and the overall health costs, and examine factors that may affect the use of health services. The findings will be used to establish effective strategies, and ensure efficiency (value-for-money) and equity (access to care) in musculoskeletal rehabilitation.
Dengue Fever Vaccine: Towards Low Cost Production And Delivery
Funder
National Health and Medical Research Council
Funding Amount
$612,039.00
Summary
With rising populations and a warming climate mosquito borne viral diseases will become more prevalent and low-cost vaccine production & delivery systems will become increasingly important. Here a microalgae based vaccine production platform will be coupled to proven Nanopatch & low cost oral vaccine delivery. The focus is on a Dengue virus vaccine, as Dengue causes 400 million infections & 100 million symptomatic cases annually.